Bioasis Technologies (FRA:107) 3-Year Dividend Growth Rate : 0.00% (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies 3-Year Dividend Growth Rate?

Bioasis Technologies's Dividends per Share for the three months ended in Nov. 2022 was €0.00.

The historical rank and industry rank for Bioasis Technologies's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:107's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Bioasis Technologies's Dividend Payout Ratio for the three months ended in Nov. 2022 was 0.00. As of today, Bioasis Technologies's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Bioasis Technologies's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Bioasis Technologies's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's 3-Year Dividend Growth Rate falls into.

Bioasis Technologies 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Bioasis Technologies (FRA:107) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Bioasis Technologies's Dividend Payout Ratio for the quarter that ended in Nov. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Nov. 2022 )	/	EPS without NRI (Q: Nov. 2022 )
	=	0	/	-0.007
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies 3-Year Dividend Growth Rate Related Terms>

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines